News Related to Heart Failure Hospitalization

Related coverage linked through entity extraction aliases.

Oral Semaglutide Reduces Heart Failure Events in Type 2 Diabetes Patients With Prior HF

Mar 03, 2026

A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.

Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes Patients

Feb 28, 2026

Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.